HK Strategy: Exposure to Europe - Who Are at Risk?
A recent surge in Eurozone sovereign yields will put pressure on some companies. The 100 largest HK companies have only 6% of their revenue from...
91 Views
China Healthcare Weekly Wrap (5-9 Oct)
Key news this week: 1) Arrivent's ph3 lung cancer study flop, 2) efgartigimod (argenx/ZLAB) discontinued in a ph3 study in Sjogren’s disease, 3)...
78 Views
GenScript Biotech (1548 HK): Placing Shares to Fund AIDD Capex Amid Accelerating Demand
GenScript is placing 77M shares (~3.5% of issued shares) at the price of HK$30.50 per share (~5% discount to undisturbed price). The placement is...
116 Views
GenScript Biotech (1548 HK): Synthetic Expert Call Transcript (11 Sep 2026)
Strong Core Profitability Inflection: GenScript’s Life Science Group (LSG) has crossed a key utilization threshold, with 1H 2026 adjusted...
101 Views
Aequitas: Genscript Biotech Placement - Earnings-Led Inflection; Re-Rating May Limit Upside
Genscript Biotech is looking to raise up to US$300m from a primary placement. Proceeds are to be used for capacity expansion and platform...
107 Views